Topcu Turkan Ozturk, Ozdemir Feyyaz, Kavgaci Halil, Gunaldi Meral, Kocoglu Hakan, Imamoglu Goksen Inanc, Mentese Ahmet, Yaman Serap Ozer, Orem Asim, Aydin Fazil
Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey.
J Cancer Res Ther. 2018 Apr-Jun;14(3):608-613. doi: 10.4103/0973-1482.174547.
Breast cancer mortality rates after metastasis is high. Urokinase plasminogen activator receptor (uPAR) and carbonic anhydrase IX (CAIX) play very important roles during tumor cell invasion and metastasis. The purpose of this study was to evaluate plasma levels of uPAR and CAIX and the effect of anthracycline-based chemotherapy on these biomarkers in patients with operable breast cancer.
Sixty-five patients and 25 age-matched healthy controls were enrolled. Levels of uPAR and CAIX were investigated before and after adjuvant chemotherapy. Basal (prechemotherapy) uPAR and CAIX levels in patients were compared with those in healthy controls and in patients after 3 cycles of chemotherapy. Levels of uPAR and CAIX were determined using the ELISA method.
uPAR and CAIX levels were significantly higher in patients (P: 0.02 and P: 0.03, respectively). Postchemotherapy uPAR and CAIX levels were higher than basal levels (P: 0.645 and P < 0.001, respectively). A cut-off value of 27.99 pg/mL for uPAR was associated with 45.31% sensitivity and 84.62% specificity, and with a positive predictive value (PPV) of 87.9% and a negative predictive value (NPV) of 38.6%. A cut-off value of 777.84 pg/mL for CAIX was associated with 90.62% sensitivity and 30.77% specificity, and with a PPV of 76.3% and an NPV of 57.1%.
We determined that uPAR and CAIX levels were higher in the fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy group than in the control group, but there was no difference between the FEC and epirubicin/adriamycin chemotherapy groups in terms of basal and postchemotherapy uPAR, CAIX levels. Furthermore, uPAR is more specific, and CAIX is more sensitive in the diagnosis of breast cancer.
乳腺癌转移后的死亡率很高。尿激酶型纤溶酶原激活物受体（uPAR）和碳酸酐酶IX（CAIX）在肿瘤细胞侵袭和转移过程中发挥着非常重要的作用。本研究的目的是评估可手术乳腺癌患者血浆中uPAR和CAIX的水平，以及蒽环类化疗对这些生物标志物的影响。
招募了65例患者和25例年龄匹配的健康对照。在辅助化疗前后检测uPAR和CAIX的水平。将患者化疗前的基础uPAR和CAIX水平与健康对照以及化疗3个周期后的患者进行比较。采用酶联免疫吸附测定（ELISA）法测定uPAR和CAIX的水平。
患者的uPAR和CAIX水平显著更高（P值分别为0.02和0.03）。化疗后uPAR和CAIX水平高于基础水平（P值分别为0.645和P<0.001）。uPAR的截断值为27.99 pg/mL时，灵敏度为45.31%，特异性为84.62%，阳性预测值（PPV）为87.9%，阴性预测值（NPV）为38.6%。CAIX的截断值为777.84 pg/mL时，灵敏度为90.62%，特异性为30.77%，PPV为76.3%，NPV为57.1%。
我们确定氟尿嘧啶、表柔比星和环磷酰胺（FEC）化疗组的uPAR和CAIX水平高于对照组，但在基础和化疗后uPAR、CAIX水平方面，FEC组与表柔比星/阿霉素化疗组之间没有差异。此外，uPAR在乳腺癌诊断中更具特异性，而CAIX更具敏感性。
